Tubulins - the target for anticancer therapy

Area of Science:

• Biochemistry
• Pharmacology
• Oncology

Background:

• Tubulin is a key target in drug discovery due to its role in cell division.
• Naturally occurring agents targeting tubulin are vital in cancer chemotherapy.
• Tubulin inhibitors are classified based on their binding sites and mechanisms of action.

Purpose of the Study:

• To review recent advancements in tubulin-interfering agents.
• To outline current trends in the development of tubulin inhibitors for cancer therapy.

Main Methods:

• Literature review of scientific publications.
• Analysis of tubulin inhibitor classification and mechanisms.
• Synthesis of recent research findings on tubulin-targeting agents.

Main Results:

• Tubulin inhibitors represent a significant class of anticancer agents.
• Classification includes colchicine site binders, vinca-alkaloid related drugs, and Taxol site binders.
• Ongoing research focuses on novel tubulin inhibitors with improved efficacy.

Conclusions:

• Tubulin remains a promising target for anticancer drug development.
• Continued research into tubulin inhibitors is essential for advancing cancer chemotherapy.
• Understanding tubulin-drug interactions guides the design of new therapeutic strategies.